Summary
Boston Scientific Corporation (BSX) has filed an 8-K report detailing the successful completion of a significant debt offering on May 12, 2015. The company raised approximately $1.83 billion in net proceeds from the issuance of three tranches of senior notes: $600 million of 2.850% notes due 2020, $500 million of 3.375% notes due 2022, and $750 million of 3.850% notes due 2025. These notes are senior unsecured obligations and rank equally with existing senior unsecured and unsubordinated indebtedness. The proceeds from this offering are earmarked for crucial strategic initiatives, including financing the acquisition of the American Medical Systems (AMS) urology portfolio and redeeming outstanding senior notes due November 2015 and June 2016. This refinancing strategy aims to optimize the company's capital structure and manage its debt maturity profile. The filing also outlines specific conditions, such as the consummation of the AMS Portfolio Acquisition, that could trigger special mandatory redemption of the 2022 notes or a repurchase offer in the event of a Change of Control Repurchase Event.
Key Highlights
- 1Completed a $1.85 billion aggregate principal amount senior notes offering.
- 2Net proceeds from the offering were approximately $1.83 billion after fees and expenses.
- 3Issued three series of notes: 2.850% due 2020 ($600M), 3.375% due 2022 ($500M), and 3.850% due 2025 ($750M).
- 4Proceeds will be used to fund the acquisition of the AMS urology portfolio.
- 5A portion of the proceeds will be used to redeem outstanding 5.500% notes due November 2015 and 6.400% notes due June 2016.
- 6The notes are senior unsecured obligations, ranking equally with other senior unsecured and unsubordinated debt.
- 7The 2022 Notes are subject to a special mandatory redemption if the AMS Portfolio Acquisition is not completed by December 31, 2015.